Edgewise Therapeutics (EWTX) Net Cash Flow (2020 - 2026)

Edgewise Therapeutics has disclosed Net Cash Flow across 7 years of filings, most recently posting -$27.9 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$27.9 million, down 438.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$16.7 million (down 185.01% YoY), and the FY2025 annual result was $19.5 million, up 143.85% from the prior year.
• Net Cash Flow came in at -$27.9 million for Q1 2026 at Edgewise Therapeutics, down from $15.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $91.4 million in Q3 2022 to a low of -$87.8 million in Q4 2022.
• The 5-year median for Net Cash Flow is $1.3 million (2024), against an average of $1.0 million.
• Across the five-year window, Net Cash Flow slumped 1856.84% in 2022 and soared 582.32% in 2025, its largest moves.
• Edgewise Therapeutics' Net Cash Flow stood at -$87.8 million in 2022, then jumped by 160.56% to $53.1 million in 2023, then plunged by 105.91% to -$3.1 million in 2024, then jumped by 582.32% to $15.1 million in 2025, then slumped by 284.46% to -$27.9 million in 2026.
• The last three Net Cash Flow figures came in at -$27.9 million (Q1 2026), $15.1 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.